Welcome to our dedicated page for Conmed news (Ticker: CNMD), a resource for investors and traders seeking the latest updates and insights on Conmed stock.
CONMED Corporation (NYSE: CNMD) is a medical equipment company in the surgical and medical instrument manufacturing industry. Its products are used in sports medicine procedures and general surgeries across specialties such as orthopedics, general surgery, gynecology, thoracic surgery and gastroenterology. The CONMED news feed on this page aggregates company-issued press releases and other coverage related to its operations, strategy and financial performance.
Recent news highlights include updates on portfolio optimization, such as CONMED’s announced intent to exit its gastroenterology product lines and to conclude a distribution agreement for a biliary stent product. The company has linked this decision to a focus on core markets in minimally invasive, robotic and laparoscopic surgery, smoke evacuation, and orthopedic soft tissue repair. News items also cover quarterly and year-to-date financial results, where CONMED reports net sales by orthopedic and general surgery categories, and by single-use and capital products, along with domestic and international growth metrics.
Investors and observers can also follow governance and leadership developments through this news stream. CONMED has issued releases about changes to its Board of Directors, including the appointment of a new independent director and the resignation of another director to take a leadership role at another organization. The company has also announced a planned transition of its Chief Financial Officer, describing the timing and advisory period associated with that change.
Other news topics include capital allocation decisions, such as the declaration of a quarterly cash dividend and the subsequent authorization of a share repurchase program with suspension of the dividend, as well as participation in healthcare investment conferences where CONMED presents investor materials and financial guidance. Users interested in CNMD can use this page to review these types of announcements over time and to see how the company describes its strategy, operations and financial outlook.
CONMED Corporation (NYSE: CNMD) has announced a definitive agreement to acquire In2Bones Global, Inc. for $145 million upfront and up to $110 million in earnout payments over four years. The acquisition, aimed at expanding CONMED's orthopedic portfolio into the extremities market, is expected to close in late Q2 or early Q3 2022, pending regulatory approval. In2Bones reported 2021 revenues of $36.8 million with 80% gross margins. The deal is projected to contribute $20 million to CONMED's revenue in H2 2022 and to be accretive to adjusted EBITDA thereafter.
CONMED Corporation (NYSE: CNMD) reported financial results for Q1 2022, with sales reaching $242.3 million, marking a 4.1% increase year over year. Domestic revenue rose 5.9%, while international revenue grew 2.2%. Diluted EPS was $0.47, up 51.6% from Q1 2021. The company raised its 2022 revenue guidance to between $1.105 billion and $1.150 billion, incorporating $20 million from the recent acquisition of In2Bones Global, subject to regulatory approval. Adjusted diluted EPS guidance is now $3.50 to $3.65.
CONMED Corporation (NYSE: CNMD) has announced a rescheduled date for its first quarter 2022 financial results due to a corporate conflict. The results will now be reported on May 4, 2022, after market close, instead of the previously scheduled April 27, 2022. A conference call will be held at 4:30 p.m. ET the same day. Updated dial-in information for the call is provided, and it will also be available via webcast. A replay will be accessible from 7:30 p.m. ET on May 4 to 11:59 p.m. ET on May 18.
CONMED Corporation (NYSE: CNMD) will announce its financial results for Q1 2022 on April 27, 2022, after market close. A conference call will follow at 4:30 p.m. ET. Investors can join the call at 1-844-889-7792 (domestic) or +1-661-378-9936 (international) with passcode 9693807. The call will also be webcast on CONMED's website. A recording will be available from 7:30 p.m. ET on the same day until 7:30 p.m. ET on May 4, 2022.
CONMED Corporation (NYSE: CNMD) announced its Annual Meeting of Stockholders will take place virtually on May 25, 2022, at 1:30 p.m. ET. Shareholders on record as of April 5, 2022 can vote. Detailed participation instructions will be provided in the proxy statement to be filed on April 15, 2022, available on the company's website. CONMED specializes in surgical devices for minimally invasive procedures across various medical specialties.
CONMED Corporation (NYSE: CNMD) has declared a quarterly cash dividend of $0.20 per share, scheduled for payment on April 5, 2022. Shareholders on record as of March 15, 2022 will be eligible for this dividend. This decision underscores the company's commitment to returning value to its shareholders. CONMED specializes in medical technology, providing surgical devices for various specialties, which positions it well within the healthcare sector.
CONMED Corporation (NYSE: CNMD) reported a strong financial performance for Q4 and full year 2021. Q4 sales reached $274.0 million, an increase of 8.4% year-over-year. Domestic revenue rose 5.0% while international sales surged 12.7%. Q4 diluted EPS stood at $0.75, down from $0.81 in 2020, yet adjusted EPS rose to $1.07 from $0.84. For 2021, total sales hit $1.01 billion, a 17.2% increase. The company anticipates 2022 revenue of $1.075 billion to $1.125 billion and adjusted EPS between $3.60 and $3.85.
CONMED Corporation (NYSE: CNMD) will present at the 40th Annual J.P. Morgan Virtual Healthcare Conference on January 10, 2022, at 9:00 a.m. ET. The presentation will feature Curt R. Hartman, Chair of the Board, President & CEO, and Todd W. Garner, Executive Vice President and CFO. Investors can access a live webcast through the Company’s website, with a replay available afterward. CONMED is a medical technology company providing surgical devices for minimally invasive procedures across various specialties.
CONMED Corporation (NYSE:CNMD) will announce its fourth-quarter 2021 financial results after market close on January 26, 2022. The company's management will host a conference call at 4:30 p.m. ET the same day to discuss these results. Interested participants can join the call via phone or webcast through CONMED's website. A recording will be available for a week following the call. The company focuses on surgical devices for minimally invasive procedures across various medical specialties.
CONMED Corporation (NYSE: CNMD) has declared a quarterly cash dividend of $0.20 per share, payable on January 5, 2022, to shareholders of record as of December 15, 2021. This decision highlights the company's commitment to returning value to its investors amidst ongoing challenges, including those posed by the COVID-19 pandemic and its impact on surgical procedures.